ClinicalTrials.gg
RecruitingNCT04914403Updated Dec 4, 2023

Mesenchymal Stem Cells for The Treatment of Frailty Syndrome

A Phase 1 interventional study of UMC119-06-05 in Frailty Syndrome, sponsored by Meridigen Biotech Co., Ltd.. Recruiting at 1 site in Taiwan. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-12-04.

Sponsored by Meridigen Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
60 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies in Frailty with a site in Taiwan — 23 open to participants now, 24 under way, none of them phase 3. Frailty · Taiwan.

Planned enrollment
53rd of 54
6 · median 94
Started
2021
with 6 others
Phase 1
2 of 68
2 open now
Primary completion
2024-12
later than 1 of 23 live
Registered
18th of 68
by date

Among the 68 studies in Frailty with a site in Taiwan, this one is the 53rd largest by planned enrollment of the 54 interventional ones that give a count, is one of 7 that started in 2021, is one of 2 in phase 1, reaches primary completion later than 1 of the 23 other live ones, and was the 18th registered.

Frailty

1,287 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

23 of the 68 studies in Frailty with a site in Taiwan are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 301 Frailty studies recruiting now, 236 (78%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 67 take healthy volunteers.

This study: 60 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Frailty with a site in Taiwan, or all of them as a file.
02

Study summary

The clinical study with UMC119-06-05 is designed to investigate the safety in patients with frailty syndrome. This will be a dose escalation, open label, single-center study in adult with frailty syndrome. UMC119-06-05 is ex vivo cultured human umbilical cord tissue-derived mesenchymal stem cells product which is intended for treatment of frailty syndrome.

Read the detailed description

Frailty syndrome is the most problematic expression of population ageing and profound implications for the planning and delivery of health and social care when population ageing is accelerating rapidly worldwide, from 461 million people older than 65 years in 2004 to an estimated 2 billion people by 2050 . Frailty syndrome characterized by a progressive decline in health and clinical symptoms of exhaustion, weight loss, a feeling of slowing down, and a decrease in functional capacity. Frailty is a common clinical syndrome in older adults that carries an increased risk for poor health outcomes including falls, incident disability, hospitalization, and mortality. Health study as meeting three out of five phenotypic criteria: low grip strength, self-reported exhaustion, slowed walking speed, low physical activity, and unintentional weight loss. Frailty is a disorder of several inter-related physiological systems, including genetic and environmental factors in combination with epigenetic mechanisms, which regulate the differential expression of genes in cells and could be especially important in ageing. Current interventions focus on interdisciplinary approaches which include nutritional supplementation, physical exercise, and cognitive intervention. Clinical studies of these preventative approaches have shown inconsistent and modest benefits, further highlighting the unmet clinical need. Therefore, development of new therapeutic modalities to improve the clinical outcomes and prognosis of frailty syndrome in adult patients is of urgent need. A variety of pharmacologic and biologic therapies are currently being tested to treat aging. Among the more innovative, experimental therapies, Mesenchymal Stromal Cells (MSCs) are represents an attractive option that addresses the pathophysiology of the syndrome.

03

Conditions studied

  • Frailty Syndrome

Browse trials for

Keywords

  • frailty syndrome
04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects of age between ≥ 60 through ≤ 85 years.
  • Subjects show signs of frailty condition as assessed by the Investigator with a Clinical Frailty scale between 4 to 6.
  • Subjects with body weight between 40 to 90 kg.
  • Subject is willing to provide written to participate in the study after reading the informed consent form and the information provided.

Exclusion criteria

Exclusion Criteria:

  • Subjects unwilling or unable to perform any of the assessments required by endpoint analysis.
  • Subjects who have a diagnosis of any disabling neurologic disorder including, but not limited to: Parkinson's disease, Amyotrophic Lateral Sclerosis, multiple sclerosis or dementia.
  • Subjects have a score on the (MMSE) of 24 or below, or have been unstable on neurological examination within the past 6 months.
  • Subjects who have a significant comorbid medical condition(s) including, but not limited to:

    1. Severe kidney disease requiring hemodialysis or peritoneal dialysis;
    2. Advanced liver disease such as hepatitis or liver cirrhosis;
    3. Severe congestive heart failure ( class 3 and 4);
    4. Severe pulmonary dysfunction, including severe stage III or IV (Gold classification)
    5. Hypothyroidism (TSH > 10 mU/L) or hyperthyroidism (TSH \< 0.1 mU/L)
  • Subjects on chronic transplant therapy.
  • Subjects who have a clinical history of within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma or in situ carcinomas.
  • Subjects using chronic immunosuppressant therapy (including prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) or TNF-alpha antagonists.
  • Subjects who are known to be infected with .
  • Subjects with known allergy or to any component of the formulation, including normal saline, human serum albumin, dimethyl sulfoxide (DMSO) and cellular therapies.
  • Subjects who have participated in another clinical study of new therapies within 6 months before the study drug administration.
  • Subjects have a history of drug or alcohol abuse within the past 3 years.
  • Subjects currently in hospital stay.
  • Any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study.
  • Subjects with uncorrected hematology test including, but not limited to:

    1. \< 8 g/dl
    2. White blood cell count \< 3,000/mm3
    3. (INR) of Coagulopathy >1.5
    4. count \< 80,000/mm3
  • Subjects who have the following conditions in laboratory tests:

    1. >2 × for (ALT) or aspartate aminotransferase (AST)
    2. Total > 1.5 mg/dl
  • Subjects who have a significant illness as judged by principal investigator (PI) including, but not limited to:

    1. Psychiatric illness
    2. Uncontrolled hypertension or hypotension (specify numeric cutoffs)
    3. Unstable cardiac arrhythmia
    4. Severe osteoarthritis or degenerative joint disease
    5. , infections
    6. History of COVID-19 in the past 4 weeks or with significant COVID-19 conditions judged by PI, or ongoing COVID-19
  • Have any condition that in the opinion of the Principal Investigator limits lifespan to \< 1 year.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    UMC119-06-05

    Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.

    Biological: UMC119-06-05

Interventions

  • BiologicalUMC119-06-05

    Cohort 1: Low does of UMC119-06-05 Cohort 2: High does of UMC119-06-05

06

What researchers measure

Primary outcomes

  1. The incidence and frequency of adverse events related to administration of UMC119-06-05.

    Incidence of Treatment-Emergent Adverse Events (TEAEs). Incidence of withdrawals due to Adverse Events(AEs).

    Time frame: 3 months from the day of administration

Secondary outcomes

  1. Changes in exercise performance using 6-min walk test (6MWT).

    The distance (meter) and walking speed (meter per seconds) in a 6-minute walk test. Improvement in clinical function as assessed by mean change in exercise performance using 6-min walk test (6MWT).

    Time frame: From baseline up to 360 days after administration.

  2. Changes in grip strength.

    Hand grip strength can be quantified by measuring the amount of static force that the hand can squeeze around a dynamometer. The force has most commonly been measured in kilograms.

    Time frame: From baseline up to 360 days after administration.

  3. Changes in quality of life measured by change in SF12 (12-Item Short Form).

    The 12-Item Short Form Health Survey (SF-12) is a 12-item measure of perceived health status with good reliability, validity and correlation with other health measures. The score is computed using the scores of the twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health and 100 indicates the highest level of health.

    Time frame: From baseline up to 360 days after administration.

  4. Changes in physical activity using International Physical Activity Questionnaire (IPAQ) questionnaire

    The IPAQ calculates the metabolic equivalent (MET) score by asking participants the days and minutes exercised in three categories of intensity (vigorous, moderate, and walking) during the previous one week. Categorical score to three levels of physical activity are Low, or Moderate, or High.

    Time frame: From baseline up to 360 days after administration.

  5. Changes in Forced Expiratory Volume in One Second (FEV1).

    Improvement in clinical function as assessed by mean change in One Second to the Forced Vital Capacity.

    Time frame: From baseline up to 360 days after administration.

  6. Changes in Clinical Frailty Scale.

    Clinical Frailty Scale evaluates specific domains, including comorbidity, function, and cognition, to generate a frailty score ranging from 1 (very fit) to 9 (terminally ill).

    Time frame: From baseline up to 360 days after administration.

07

Study locations

1 of 1 sites recruiting
  • Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare.
    New Taipei City, 23561, Taiwan
    Recruiting
    • Claire Liao, MS · ContactClaire.Liao@meridigen.com · +886-2-8978-7777
    • Joseph Chen, MS · Contactjoseph.chen@meridigen.com · +886-2-8978-7777
    • Shih-Wei Huang, M.D., Ph. D. · Principal investigator
    • Tsan-Hon Liou, M.D., Ph. D. · Sub investigator
    • Hung-Chou Chen, M.D. · Sub investigator
    • Lung Chan, M.D., Ph. D. · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2021 (actual). Primary completion is estimated for Dec 2024, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2021
First posted
Jun 4, 2021
StartActual
Sep 1, 2021
Primary completionEst.
Dec 2024
CompletionEst.
Jul 2025
Last update
Dec 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04914403
Lead sponsor
Meridigen Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Jun 4, 2021
Start date
Sep 1, 2021
Primary completion
Dec 2024 (estimated)
Completion
Jul 2025 (estimated)
Last update
Dec 4, 2023

Study contacts

Claire Liao, MS
Contact
claire.liao@meridigen.com
+886-2-8978-7777 ext. 19965
Joseph Chen, MS
Contact
joseph.chen@meridigen.com
+886-2-8978-7777 ext. 19905

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion